Kim KM, et al. - This study was designed to determine the impact of 20 mg rosuvastatin on biomarkers, including paraoxonase-1 (PON-1) and asymmetric dimethylarginine (ADMA), and on microvascular reactivity in dyslipidemic patients with type 2 diabetes. Improved microvascular reactivity with concomitant beneficial changes in the postprandial levels of PON-1 and ADMA were reported as the consequences of rosuvastatin treatment for 12 weeks. Overall, findings indicated that rosuvastatin improves the postprandial cardiometabolic milieu in type 2 diabetes.